Key result
Cardiac contractility modulation linked to improved LV FV, functional class, and NT-proBNP in CHF and AF.
Why the study?
The study was conducted to evaluate the effectiveness of cardiac contractility modulation in patients with chronic heart failure and atrial fibrillation.
Does cardiac contractility modulation (MSS) improve cardiac function and heart failure severity in patients with chronic heart failure and atrial fibrillation?
Observational (n=40)
Does cardiac contractility modulation (MSS) improve cardiac function and heart failure severity in patients with chronic heart failure and atrial fibrillation?
Cardiac contractility modulation may improve left ventricular function, functional class, and NT-proBNP levels in patients with chronic heart failure and atrial fibrillation.
Hypothesis-generating for cardiac contractility modulation in CHF-AF; leaves open randomized confirmation before practice change.
AIM: to evaluate the effectiveness of cardiac contractility modulation (MSS) in patients with chronic heart failure (CHF) and atrial fibrillation (AF). MATERIALS AND METHODS: The following studies were performed in 40 patients with CHF and AF before implantation of the MSS device and after 2 and 6 months of follow-up: 12-channel ECG, transthoracic EchoCG, 6-minute walk test, determination of the level of Pro-natriuretic N-terminal peptide (NT-proBNP), daily ECG monitoring, and a questionnaire based on the Minnesota quality of life questionnaire for patients with CHF (MHFLQ). All patients received long-term optimal drug therapy for CHF before surgery. RESULTS: The results obtained indicate a statistically significant positive effect of the use of MSS in patients with CHF and AF on LV FV, the functional class of CHF, and levels of NT-proBNP regardless of the etiology of CHF. CONCLUSION: The use of MSS may be promising for the treatment of heart failure in patients with CHF and AF.
No takes yet. Share an insight, caveat, or question.
Uskach et al. (2020) conducted an observational in Chronic heart failure and atrial fibrillation (n=40). Cardiac contractility modulation (MSS) vs. Baseline (before implantation) was evaluated on LV FV, functional class of CHF, and levels of NT-proBNP. In 40 patients with CHF and AF, cardiac contractility modulation significantly improved LV FV, CHF functional class, and NT-proBNP levels at 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: